Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach.
Nimish J ThakoreBrittany R LapinTyler G KinzyErik P PioroPublished in: Amyotrophic lateral sclerosis & frontotemporal degeneration (2018)
King's and FT9 are more sensitive to observed progression of disease in clinical trials than MITOS. FT9 can partition the course similar to King's, and may have advantages of sequential progression and easy applicability to retrospective data. Markov transition intensity estimates may be of value for counseling, health economic studies, and research design. In particular, this framework permits estimation of multidimensional effects of variables (including treatment) on outcome.
Keyphrases
- amyotrophic lateral sclerosis
- clinical trial
- healthcare
- public health
- mental health
- randomized controlled trial
- cross sectional
- machine learning
- high intensity
- hepatitis c virus
- risk assessment
- human immunodeficiency virus
- artificial intelligence
- combination therapy
- health promotion
- phase ii
- hiv infected
- antiretroviral therapy